Hematology profile, digestive enzymes, thyroid hormones, productivity, and nitrogen balance of growing male rabbits supplemented with exogenous dietary lysozyme.

In a simple randomized design trial, 420 growing male V-Line rabbits were randomly distributed into four groups to investigate the impact of exogenous dietary lysozyme on some physiological and nutritional parameters of male growing rabbits supplemented with exogenous dietary lysozyme. The witness group received a basal diet without exogenous dietary lysozyme (LYZ0), while the exogenous dietary lysozyme groups received 50, 100 and 150 mg/kg of basal diet (Groups; LYZ50, LYZ100 and LYZ150), respectively. The results showed significantly increased in blood cell count, hemoglobin concentration, total white blood cell, lipase, protease, amylase, total protein, triiodothyronine and thyroxine levels, while thyroid stimulating hormone levels significantly lessened in rabbits received LYZ. The LYZ- rabbit diets improved total digestible nutrient, digestible crude protein, and digestible energy values, with the LYZ100 group outperforming the others. LYZ-treated rabbits had significantly higher nitrogen intake, digestible nitrogen, and nitrogen balance than the witness group. The lysozyme in a rabbit's diet is taking on a new role as a digestive enzyme, enhancement thyroid hormones, as well as improvement hematology, daily protein efficiency ratio, daily performance index, hot carcass, total edible parts, nutritional value, and nitrogen balance, with decreasing the daily caloric conversion ratio and total non-edible parts.

The Effect of Exogenous Lysozyme Supplementation on Growth Performance, Caecal Fermentation and Microbiota, and Blood Constituents in Growing Rabbits.

The effects of exogenous lysozyme supplementation (LYZ) on growth performance, caecal fermentation and microbiota, and blood characteristics were investigated in growing rabbits. A total of 420 growing male V-Line rabbits (30 d old; weighing 528 ± 16 g) were randomly divided into four groups of 105 rabbits each, and monitored for 42 days. Experimental groups included a control group (LYZ0) fed a basal diet without LYZ supplementation, and three treated groups fed the same basal diet supplemented with LYZ at 50, 100, and 150 mg/kg diet, respectively. The results showed a quadratic improvement in the final body weight, daily growth rate, FCR, and digestibility of DM, while the digestibility of OM, CP, EE, NDF, and ADF improved linearly when LYZ supplementation was increased. The dressing percentage increased quadratically when LYZ levels were increased in the rabbit diets. In rabbits fed LYZ diets, L. acidophilus counts increased linearly (p < 0.05) and L. cellobiosus, and Enterococcus sp. counts increased quadratically, whereas E. coli counts decreased. In the LYZ-supplemented groups, the caecal pH value and NH3-N concentration declined quadratically, whereas total VFA, acetic, and butyric acids increased. Total lipids decreased linearly, whilst triglycerides and cholesterol decreased quadratically with LYZ supplementation. Total antioxidant capacity, superoxide dismutase, glutathione S-transferase, and catalase increased quadratically, while malondialdehyde decreased linearly in the LYZ-supplemented groups. In conclusion, exogenous lysozyme administration improved rabbit growth performance and antioxidant status while lowering the blood lipid profile, altering the bacterial population, and regulating caecal fermentation. Therefore, LYZ up to 150 mg/kg can be used as a potential supplement in rabbit feed.

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin.

AIMS: The purpose of this study is to present our center's experience in managing patients with pulmonary arterial hypertension (PAH). The main objective is to describe patients' management profile and treatment outcome. METHODS: This study presents the results from a single pulmonary hypertension (PH) specialized center in Saudi Arabia. Both incidence and prevalence cases are included. We have previously reported the clinical and physiological characteristics at the time of diagnosis for this cohort of patients. In this study, we describe the clinical management and the outcome of therapy in the same cohort, who were prospectively followed for a mean of 22 months. RESULTS: A total of 107 patients were identified as having PAH. At the time of enrollment, 56.1% of patients were in modified New York Heart Association functional class (NYHA FC) III and 16.8% were in IV. Phosphdiesterase-5 inhibitor was the most commonly used target therapy (82.2%) followed by endothelin receptors antagonist (74.4%). Only five patients (4.7%) were candidate to use calcium channel blockers. Seventy-nine patients (73.8 %) received a combination nonparenteral target therapy. Thirty-one patients (28.9%) died during the follow-up period. Modified NYHA FC III and IV patients, portopulmonary hypertension, heritable PAH, and PAH associated with connective tissue diseases had the highest mortality rate (P < 0.001). CONCLUSION: Our patients are detected at advanced stage of the disease, and thus the mortality is still unacceptably high. Advanced functional class at presentation and certain disease subgroups are associated with increased mortality.